The Leucovorin Calcium Injection Market is expanding as demand for supportive cancer-care therapies and treatments for folate-related conditions increases. Leucovorin calcium is used in clinical settings for folate deficiency, megaloblastic anemia, and prevention of methotrexate toxicity. The growing prevalence of cancer and increasing use of chemotherapy are important factors supporting market development.

According to a recent report by Wise Guys Report, the market was estimated at approximately USD 0.75 billion in 2023 and is projected to reach USD 1.232 billion by 2032, representing a CAGR of about 5.69% during the forecast period.

The market is segmented by administration route, application, strength, formulation, and end user. Injection remains an important route because of its use in hospital-based treatment and supportive-care settings. Vials and pre-filled syringes provide healthcare professionals with different administration options.

Hospitals represent a major end-user segment, while clinics and home healthcare settings also contribute to demand. North America is expected to remain a leading regional market, supported by established healthcare infrastructure and cancer-treatment capabilities. Asia-Pacific offers promising opportunities as healthcare access and pharmaceutical infrastructure expand.

Future market growth is likely to be influenced by increasing cancer prevalence, personalized medicine, improved drug-delivery technologies, and expanding access to supportive therapies.

Frequently Asked Questions

What is leucovorin calcium injection used for?
It is used for folate-related conditions and to help prevent methotrexate toxicity.

What is driving market growth?
Cancer prevalence, chemotherapy use, and demand for supportive care are key factors.

What is the projected market size by 2032?
The market is projected to reach approximately USD 1.232 billion by 2032.